Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
08/2005
08/03/2005EP1142890B1 Aminopyrazole derivatives
08/03/2005EP1131344B1 Retro-inversion peptides that target gastro-intestinal tract transport receptors and use thereof
08/03/2005EP1071671B1 Triazolones with a neuroprotective action
08/03/2005EP0998288B2 Compositions containing capsaicin or capsaicin analogues and a local anesthetic
08/03/2005EP0815231B1 Use of neuronal apoptosis inhibitor protein (naip)
08/03/2005CN1650169A Methods of screening apoptosis modulating compounds, compounds identified by said methods and use of said compounds as therapeutic agents
08/03/2005CN1649884A Novel azacyclic ethynyl derivatives
08/03/2005CN1649876A 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
08/03/2005CN1649875A 2-thia-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
08/03/2005CN1649871A Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl-6, 7, 8, 9-tetrahydropydimido[1, 2-a]pyrimidin-4-one derivatives
08/03/2005CN1649869A Azaindoles as inhibitors of c-Jun N-terminal kinases
08/03/2005CN1649867A Novel 1, 2, 3-substituted indolizine derivatives, inhibitors of FGFs, method for making same and pharmaceutical compositions containing same
08/03/2005CN1649865A Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
08/03/2005CN1649862A Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgestics
08/03/2005CN1649857A Hydroxamic acid derivatives
08/03/2005CN1649855A Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
08/03/2005CN1649853A Thiazolidinones compound, its preparing method and use as medicine
08/03/2005CN1649849A Tachykinin receptor antagonists
08/03/2005CN1649848A Fused pyrimidines derivatives as antagonists of the corticotropin releasing factor (CRF)
08/03/2005CN1649845A Muscarinic antagonists
08/03/2005CN1649844A Isoquinoline derivatives
08/03/2005CN1649843A Novel chalcone derivatives and uses thereof
08/03/2005CN1649842A 2, 6-quinolinyl and 2, 6-naphthyl derivatives, processes for preparing them and their uses as VLA-4 inhibitors
08/03/2005CN1649841A Piperidine derivative compound and drug containing the same compound as active ingredient
08/03/2005CN1649826A 5-amino-1-pentene-3-ol substituted derivatives
08/03/2005CN1649819A Novel thyroid receptor ligands
08/03/2005CN1649624A Use of TNF alpha antibodies and another drug
08/03/2005CN1649623A Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
08/03/2005CN1649611A Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent
08/03/2005CN1649608A Composition comprising the extract of cistanche deserticola Y.C. ma showing enhancing activity of the neurite outgrowth and neurotrophic effects
08/03/2005CN1649602A Re-epithelializing pharmaceutical compositions comprising xanthan gum
08/03/2005CN1649599A Substituted aminoalkanephosphonic acids for the treatment ofneuropathic pain, affective and attention disorders, schizophrenia, tinnitus, myopia and other ocular disorders
08/03/2005CN1649597A Pharmaceutical compositions containing water-soluble prodrugs of propofol and methods of administering same
08/03/2005CN1649595A Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy
08/03/2005CN1649593A Use of 2-alkoxyphenyl-substituted imidazotriazinones
08/03/2005CN1649589A The treatment of pain with ifendropil
08/03/2005CN1649587A Use of epothilones in the treatment of brain diseases associated with proliferative processes
08/03/2005CN1649582A Amino-methyl substituted tetracycline compounds
08/03/2005CN1649581A Substituted 3-amino-thieno(2, 3-b)pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
08/03/2005CN1649577A Preventing and/or treating cardiovascular disease and/or associated heart failure
08/03/2005CN1649569A Controlled release dosage forms
08/03/2005CN1648136A Companumoea root polyose, derivative and its preparing method and use
08/03/2005CN1648135A Transduction peptide-humanized chloine acetylase fusion protein and its use
08/03/2005CN1647816A Process for preparing decumbent corydalis tuber total alkaloid and its preparation and quality detecting method
08/03/2005CN1647801A Staphylococcus aureus metabolic product medicine oral preparation and its use
08/03/2005CN1213044C Amine and amide derivatives as ligands for neuropeptide YY5 receptor useful in treatment of obesity and other disorders
08/03/2005CN1213029C S-Ht receptor agonist and its preparing method for salt
08/03/2005CN1213028C Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl IV, processes for their preparation, and their use
08/03/2005CN1213020C Phenylalaninol derivatives
08/03/2005CN1212845C Use of low-molecular-weight heparins for preventing and treating central nervous system trauma
08/03/2005CN1212844C Helicid powder injection preparation and its preparation method
08/03/2005CN1212842C Melazocine masticatory and its preparation
08/03/2005CN1212841C Amelioration of apomorphine adverse effects
08/03/2005CN1212838C Controlled-release dosage forms comprising zolpidem or salt thereof
08/03/2005CN1212836C Compositions for ameliorating attention-deficient/hyperactivity disorder
08/03/2005CN1212835C Hydroxamate-containing cysteine and serine protease inhibitors
08/03/2005CN1212834C Fluoxetine enteric soluble micro-capsule
08/03/2005CN1212831C Pharmaceutical preparations
08/03/2005CN1212809C Subcutaneous implant
08/03/2005CA2479385A1 Use of propargylamine as neuroprotective agent
08/02/2005US6924415 Identified as a target for therapeutic intervention due to its role in molecular events that lead to or contribute to cardiac hypertrophy and/or dilated cardiomyopathy
08/02/2005US6924374 Modulators of dopamine neurotransmission
08/02/2005US6924314 Compounds for the treatment of metabolic disorders
08/02/2005US6924309 Modulation cystic fibrosis; antiinflammatory agents; antiallergens; rheumatic diseases; autoimmune diseases
08/02/2005US6924305 Diazocine derivatives and their use as tryptase inhibitors
08/02/2005US6924303 Analgesic and anti-inflammatory compositions containing COX-2 inhibitors
08/02/2005US6924297 Naphathalene derivatives which bind to the EP4 receptor
08/02/2005US6924290 Antitumor agents; anticancer agents; sexual disorders; cardiovascular disorders
08/02/2005US6924289 Useful for treating or preventing a disorder or condition selected from hypertension, depression, anxiety, phobias, post trauma stress, sexual disfunction, eating disorder, obesity, Alzheimer's disease, Parkinson's disease etc.
08/02/2005US6924288 Enantiomerically pure opioid diarylmethylpiperzine and methods of using same
08/02/2005US6924284 PARP inhibitors
08/02/2005US6924280 Dipeptide derivatives
08/02/2005US6924278 Heterocyclic carboxy amines such as (2R)-1-[3,5-Bis(trifluoromethyl)benzoyl]-4-[4-((3S)-3-ethylmorpholino)-2-butynyl]-2-[(1H-indol-3-yl)methyl]piperazine, used as substance P and neurokinin antagonist for prophylaxis of diseases
08/02/2005US6924277 Central nervous system disorders; antidepressants; bipolar disorders; rhematic diseases
08/02/2005US6924276 Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
08/02/2005US6924272 Medicinal composition for diabetic neuropathy
08/02/2005US6924100 Nucleotide sequences coding preferential polypeptide for use in the treatment and diagnosis of cardiovascular disorders and headaches
08/02/2005US6923988 Solid carrier includes a hydrophililc surfactant and a drug
08/02/2005US6923981 Fast dissolving orally consumable films
08/02/2005CA2446939C Pyridylpyrimidine derivatives as effective compounds against prion diseases
08/02/2005CA2370376C Anhydrous mirtazapine crystals and process for the production thereof
08/02/2005CA2321639C Bicyclo[2.2.1]heptanes and related compounds
08/02/2005CA2190837C Transdermal delivery of anti-epileptic drugs
08/02/2005CA2190087C Nitro compounds and their compositions having anti-inflammatory, analgesic and anti-thrombotic activities
08/02/2005CA2165824C Use of modafinil for the treatment of sleep apnea and ventilation problems of central origin
08/02/2005CA2154577C Novel inhibitors of adenosine monophosphate deaminase
08/02/2005CA2132537C Basic derivatives of glutamic acid and aspartic acid as gastrin or cholecystokinin antagonists
08/02/2005CA2091370C Tablets, granulates and pellets with a high active substance content for highly concentrated, solid dosage forms
07/2005
07/28/2005WO2005068467A1 Novel fused-ring compound
07/28/2005WO2005067954A1 A pharmaceutical composition comprising the extract of sorbus amurensis koehne for treating or preventing cerebrovascular system disease
07/28/2005WO2005067950A1 Kava-kava extract for reducing the toxic and side effects and composition comprising the same and preparation thereof
07/28/2005WO2005033102A3 Thiophene-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
07/28/2005WO2005032234A3 Agent for reducing ill effects of acute alcohol intoxication
07/28/2005WO2003072035A8 Compositions and methods for the treatment of immune related diseases
07/28/2005WO2002055010A3 Pharmaceutical compositions comprising modified cns-derived peptides for promoting nerve regeneration and prevention of nerve degeneration
07/28/2005US20050166274 Compositions and methods for the diagnosis and treatment of tumor
07/28/2005US20050165259 Cannabinoids
07/28/2005US20050165256 Aminating compounds such as 3,5-dichloroaniline in the presence of ammonia and a catalyst selected from the group consisting of copper salts, cupric and cuprous oxides and mixtures, heating and pressurization
07/28/2005US20050165244 precipitating the citalopram base in crystalline form, and transforming the base into a pharmaceutically acceptable citalopram salt; useful for removing intermediates which are structurally closely related to citalopram
07/28/2005US20050165232 Phenyl substituted imidaopyridines and phenyl substituted benzimidazoles
1 ... 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 ... 1833